SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.
The activity of a new water-soluble molecule, SCH 38057, against picornaviruses is described. SCH 38057 inhibited plaque formation of selected entero- and rhinoviruses in a range of 10.2 to 29.1 microM (50% endpoint) and had a therapeutic index of 10 against poliovirus type 2 (polio 2) in HeLa cells. When administered orally or subcutaneously, SCH 38057 protected mice infected with either coxsackievirus B3 (CVB3) or echovirus-9 from mortality. The molecule provided a low level of protection against thermal inactivation of virus, indicating that SCH 38057 interacts with the picornavirus capsid. Binding studies with [3H]SCH 38057 revealed that the molecule binds to CVB3 and human rhinovirus 14 (HRV14) in a ratio of 29 and 19 molecules per viral particle, respectively. The affinity constant for SCH 38057 binding to CVB3 was 7.0 x 10(-4) M. When added to cultures of infected cells at 3 h after infection, SCH 38057 markedly inhibited viral RNA synthesis. This finding with lack of inhibition of attachment and loss of infectious virus after attachment were interpreted to indicate that, although SCH 38057 binds to the viral capsid, the molecule exerts its antiviral effect after the initial stage of picornavirus uncoating, i.e., after conversion of the 156S infectious viral particle to smaller subviral species.
Schering-Plough Research Institute, Kenilworth, NJ 07033-0539.
E
E
Rozhon
S
S
Cox
P
P
Buontempo
J
J
O'Connell
W
W
Slater
J
J
De Martino
J
J
Schwartz
G
G
Miller
E
E
Arnold
A
A
Zhang
D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D002213:Capsid / Q000187:drug effects / Q000378:metabolism*; D029822:Enterovirus B, Human / Q000187:drug effects / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D007093:Imidazoles / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D007555:Isoxazoles / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D010849:Picornaviridae / Q000187:drug effects* / Q000378:metabolism* / Q000502:physiology; D017955:Poliovirus / Q000187:drug effects / Q000378:metabolism; D012229:Rhinovirus / Q000187:drug effects / Q000378:metabolism; D013810:Therapeutic Equivalency
D000998:Antiviral Agents; D007093:Imidazoles; D007555:Isoxazoles; C080822:1-(6-(2-chloro-4-methoxyphenoxy)hexyl)imidazole hydrochloride; C045978:disoxaril